HiLabs and Harvard Researchers Partner to Study Ghost Networks in Medicare Advantage

Jul 6, 2026
HiLabs has announced a multi-year research collaboration with Dr. Thomas Tsai of Harvard University to analyze ghost networks and access to care for 35 million Medicare Advantage enrollees.

HiLabs and Dr. Thomas Tsai of Harvard University have begun a multi-year collaboration to examine provider network adequacy and ghost networks within Medicare Advantage plans, announced in a press release.

The research will measure access to care and identify gaps between listed and accessible providers across the 35 million Americans enrolled in Medicare Advantage. HiLabs will contribute real world provider data and its AI powered ghost network detection to support this work.

Dr. Tsai, a faculty member at the Harvard T.H. Chan School of Public Health and Harvard Medical School, will lead studies assessing network adequacy, provider availability, and the impact of inaccurate directories on patient outcomes.

HiLabs delivers data intelligence tools that help health plans meet federal network and directory accuracy standards. The collaboration’s findings will inform regulators and health plan leaders about where provider access gaps are most severe and how to improve network reliability nationwide.

We hope you enjoyed this article

Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

Market report

2025 Generative AI in Professional Services Report

Thomson Reuters

This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.

Read more
Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.